Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941253 | 0.80 | ALDH1A1 (0.37) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL3601953 | 0.62 | ABCB1 (0.43) | L3MBTL1KDM4EALDH1A1ALOX5 | |
| SCHEMBL27205449 | 0.60 | GAA (0.65) | GAAKDM4E | |
| SCHEMBL8948353 | 0.57 | ALDH1A1 (0.39) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL5652687 | 0.57 | ALDH1A1 (0.48) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL5645967 | 0.56 | GAA (0.49) | GAAALDH1A1 | |
| SCHEMBL8061320 | 0.56 | ALDH1A1 (0.49) | GAAALDH1A1 | |
| SCHEMBL22051105 | 0.56 | ALDH1A1 (0.48) | GAAALDH1A1 | |
| SCHEMBL27570229 | 0.56 | KMT2A (0.56) | L3MBTL1ALDH1A1ALOX5 | |
| SCHEMBL23092598 | 0.56 | ALDH1A1 (0.49) | L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | GAA 4740/4885L3MBTL1 1399/4885KDM4E 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.